Earnings watch · TLX · Healthcare

Telix Pharmaceuticals Limited (TLX) enters earnings week with weak relative strength

The oncology radiopharmaceuticals developer has recovered over 12 weeks, but its shorter-term tape remains uneven before the June 18 report.

Telix Pharmaceuticals Limited
Latest9.560 USD
1W move2.8%
Volume1.1x
TrendActive
Biotechnology radiopharmaceuticals lab with oncology research equipment and market data screens.

Market update

What happened

Telix Pharmaceuticals Limited (TLX) closed at $9.56 in the latest weekly market data, rising 2.8% for the week as investors look toward its scheduled June 18 earnings report. The company is expected to report for the fiscal quarter ended March 31, with an estimate of -$0.01 per share.

The setup is mixed. Shares are still down -9.5% over four weeks, while the 12-week return stands at 9.3%; volume was 1.09 times the 13-week average. Market Dynamics shows modest confirmation at 0.44, but Relative Strength remains weak at -21.3. The weekly price path over 52 weeks provides longer-term context rather than live intraday action.

Continue your research

Explore TLX across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Short interestReview short positioning, crowding and possible squeeze risk.

TLX coverage

Evidence context